← Back to patent-cliff list
CAS 74-88-4
Iodomethaneiodomethane-11CMethyl iodide
Codes: (I)270899-4-a, LACO-011, (XXXIV)638294-1-d, (XXXVI)101438-55-d, Ephedrine Sulfate-019, Clarithromycin-025, Desvenlafaxine-024, (X)1225102-1-a, (IV)909096-2-a, (XXIX)796686-1-d, (XXXIII)145089-2-d, Granisetron-009 +3 more
Application context (from source-drug indications)
Major depressive disorderEsketamine HydrochlorideSuicidal ideationEsketamine HydrochlorideDepressive disorderEsketamine HydrochlorideAnaesthesiaEsketamine HydrochlorideTreatment-resistant depressionEsketamine HydrochloridePainEsketamine HydrochlorideTonic-clonic seizureLacosamideEpilepsyLacosamidePartial-onset seizureLacosamideSeizureLacosamideSystolic heart failureFinerenoneDiastolic heart failureFinerenoneHeart failureFinerenoneChronic renal impairmentFinerenoneDiabetic nephropathyFinerenoneType 2 diabetesFinerenoneBreast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateHypotensionEphedrine SulfateMarginal zone B-cell lymphomaClarithromycin/Rabeprazole Sodium/AmoxicillinDuodenal ulcerClarithromycin/Rabeprazole Sodium/AmoxicillinImmune thrombocytopenic purpuraClarithromycin/Rabeprazole Sodium/AmoxicillinGastric ulcerClarithromycin/Rabeprazole Sodium/AmoxicillinGastritisClarithromycin/Rabeprazole Sodium/AmoxicillinHelicobacter pylori infectionClarithromycin/Rabeprazole Sodium/AmoxicillinMajor depressive disorderDesvenlafaxineDepressive disorderDesvenlafaxinePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelSinusitisClarithromycinTonsillitisClarithromycinAcute bronchitisClarithromycinChronic bronchitisClarithromycinLower respiratory tract infectionClarithromycinPharyngitisClarithromycinNon-small cell lung cancerFulzerasibColorectal cancerFulzerasibSolid tumourFulzerasibNon-small cell lung cancerIruplinalkib侵袭性念珠菌病Rezafungin acetateCandidiasisRezafungin acetateCandidaemiaRezafungin acetate卡氏肺囊虫感染Rezafungin acetate侵袭性真菌感染Rezafungin acetateAspergillus infectionRezafungin acetateAlzheimer's diseaseRivastigmine TartrateDementiaRivastigmine TartrateParkinson's diseaseRivastigmine Tartrate抗胆碱能综合征Rivastigmine Tartrate神经行为学表现Rivastigmine TartrateCognitive impairmentRivastigmine TartrateChemotherapy-induced nausea and vomitingGranisetronNauseaGranisetron呕吐Granisetron手术后恶心呕吐GranisetronPostoperative painGranisetronGastroparesisGranisetronNon-small cell lung cancerZongertinibLung cancerZongertinib食道腺癌Zongertinib食管胃结合部肿瘤ZongertinibGastric cancerZongertinibMetastatic breast cancerZongertinibHot flushesElinzanetantVasomotor symptomsElinzanetantHR阳性乳腺癌Elinzanetant睡眠障碍ElinzanetantMenopausal symptomsElinzanetantOpioid dependenceElinzanetant
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Esketamine Hydrochloride | Tier B — Position early | 2029 |
| Lacosamide | Tier B — Position early | 2028 |
| Finerenone | Tier C — Watch / trade | 2030 |
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Ephedrine Sulfate | Tier C — Watch / trade | - |
| Clarithromycin/Rabeprazole Sodium/Amoxicillin | Tier C — Watch / trade | - |
| Desvenlafaxine | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Clarithromycin | Tier C — Watch / trade | - |
| Fulzerasib | Tier C — Watch / trade | - |
| Iruplinalkib | Tier C — Watch / trade | - |
| Rezafungin acetate | Tier C — Watch / trade | - |
| Rivastigmine Tartrate | Tier B — Position early | - |
| Granisetron | Tier C — Watch / trade | - |
| Zongertinib | Tier C — Watch / trade | - |
| Elinzanetant | Tier C — Watch / trade | - |
| Eptazocine hydrobromide | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Iodomethane→Chlorocyclopentane→1-Chloro-2-cyanobenzene→(2-Chlorophenyl)(cyclopentyl)methanone→2-Chlorobenzoyl chloride→Cyclopentene→(1-Bromocyclopentyl)(2-chlorophenyl) ketone→Aminomethane→1-[(E)-(2-Chlorophenyl)(methylimino)methyl]cyclopentan-1-ol hydrogen chloride→(±)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride→2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one→(2S)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
1,3-Dihydroxy-2,2-dimethylpropane→2,2-Dimethylcyclohexane-1,3-dione→2,2,4-Trimethylcyclohex-3-en-1-one→2,4,6-Triisopropyl-N'-[(1Z)-2,2,4-trimethylcyclohex-3-en-1-ylidene]benzenesulfonohydrazide→2,4,6-Triisopropylbenzenesulfonohydrazide→3,3,7,7-Tetramethyl-1,5-dioxaspiro[5.5]undecan-8-one→3,3,7,7,9-Pentamethyl-1,5-dioxaspiro[5.5]undec-8-ene→3,5-Cyclohexanedione→4-Methyl-N'-[(8E)-3,3,7,7-tetramethyl-1,5-dioxaspiro[5.5]undec-8-ylidene]benzenesulfonohydrazide→4-Methylbenzenesulfonhydrazide→Iodomethane
Cinnamyl alcohol→(±)-3-(Benzyloxy)-2-bromo-3-phenylpropan-1-ol→(±)-2-[(Benzyloxy)(phenyl)methyl]oxirane→(2R)-2-[(R)-(Benzyloxy)(phenyl)methyl]oxirane→(1R,2R)-1-(Benzyloxy)-1-phenylpropan-2-ol→(1R,2R)-1-(Benzyloxy)-1-phenylpropan-2-yl methanesulfonate→[(1R,2S)-2-Azido-1-(benzyloxy)propyl]benzene→Benzyl [(1R,2S)-1-(benzyloxy)-1-phenylpropan-2-yl]carbamate→Methyl iodide→Benzyl [(1R,2S)-1-(benzyloxy)-1-phenylpropan-2-yl]methylcarbamate→(-)-2(S)-(Methylamino)-1(R)-phenylpropan-1-ol
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | N-Boc-O-Benzyl-D-serine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | N-[6-Chloro-4-(4-fluoro-2-methylp henyl)-3-pyridinyl]-N,a,a-trimethy Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 3-Morpholinemethanol, 4-(phenylmethyl)-, hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (7S,9aS)-7-((Benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine dioxalate salt Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | ((7S)-octahydropyrazino[2,1-c][1,4]oxazin-7-yl)methanol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-Boc-3-morpholinecarboxylic Acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-(3,5-bis-trifluoromethylphenyl)-2-methyl-propionyl chloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 4-Bromo-2-methoxybenzaldehyde Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-formyl-3-methoxybenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-AMino-5-Methylpyridin-2-ol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-5-methylpyridin-4-amine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Cyanoethyl 3-oxobutanoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.